FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2055006945> ?p ?o ?g. }

• W2055006945 endingPage "5" @default.
• W2055006945 startingPage "5" @default.
• W2055006945 abstract "to be deemed bone marrow carcinosis. Matrix bone metastases were demonstrated in 78% of patients with bone marrow carcinosis versus only 16% of the patients without bone marrow carcinosis. Heavy tumour infiltration of the bone marrow was associated with multiple bone lesions with histopathologic evidence of bone destruction [5]. This study provided evidence that the primary soil of metastatic bone disease in breast cancer is the bone marrow. Bone metastases are the result of invasion and destruction of bone tissue matrix mostly by tumour cells from within the marrow cavity. Intuitively, if bone marrow carcinosis heralds progression, the presence of even a small number of metastatic cells within the bone marrow should correlate with poor outcome. Disseminated carcinoma cells (DTCs) are clearly detectable in the bone marrow very early in the diagnosis of many solid tumours [6]. DTCs are distinct from frank bone marrow carcinosis as they are not associated with marrow dysfunction. However, clearly both exist on a continuum. Cells appear to disseminate from early primary lesions and then acquire additional genetic defects. Gene expression patterns of DTCs are often strikingly similar to the cells from the primary tumour [6]. The bone marrow may form the preferred reservoir for metastatic tumour cells, from where they re-circulate to distant organs where better growth conditions exist. The presence of DTCs in the bone marrow of primary breast cancer patients is an independent prognostic indicator of relapse, correlating with the appearance of bone metastases and with the occurrence of overt metastasis at other sites [7]. Significant correlations have been shown between DTCs in the bone marrow and metastatic relapse [8]. Animal models indicate that a significant proportion of DTCs remain dormant or perish, never developing into overt metastases [9]. Dormancy can be defined as slow-growing tumours that appear after long latency periods, quiescent tumours with no growth at all, or tumours that are in proliferaThe occurrence of overwhelming bone marrow infiltration by solid tumour cells is rarely reported. Despite the paucity of published data, this is not rare clinically and is often seen as a late-stage event. The article by Florcken and colleagues in the October 2009 issue of OnkOlOgie is indeed relevant [1]. The authors state that where bone marrow carcinosis has been reported it is usually associated with a large burden of disease, rapid progression and death. Yet there have been positive reports of long-term disease control in bone marrow carcinosis caused by solid tumours [2, 3]. The 63-year old female patient described by Florcken and colleagues died within 5 months of initial presentation [1]. The diagnosis of metastatic renal cell cancer was confirmed after investigation of thrombocytopenia. This is an unusual complication of renal cell cancer and to our knowledge the first reported case. Unexplained or progressive cytopenias in cancer patients should raise the possibility of bone marrow carcinosis. For patients without a cancer diagnosis, though other causes of bone marrow failure should be investigated, early bone marrow biopsy may help to diagnose the primary site of malignancy. Nuclear medicine bone scan and bone marrow biopsy are required to establish the diagnosis of disseminated carcinomatosis of the marrow. Bone scintigraphy commonly demonstrates a super-scan of malignancy. Bone marrow trephine generally exhibits the highest yield for detecting metastatic disease, as aspiration may prove unsuccessful due to fibrosis [4]. The marrow serves as a reservoir of tumour cells with the potential to metastasise. The physical burden of tumour cells within the bone marrow may eventually interfere with haematopoiesis, haemostasis and immune responses. Bone marrow carcinosis then becomes clinically significant, often compounded by myelosuppressive cytotoxics. The incidence of bone marrow carcinosis was investigated in 380 breast cancer patients at the time of first recurrence. 87 patients (23%) had sufficient tumour cells in the bone marrow" @default.
• W2055006945 created "2016-06-24" @default.
• W2055006945 creator A5027057994 @default.
• W2055006945 creator A5055782327 @default.
• W2055006945 creator A5088951258 @default.
• W2055006945 date "2010-01-01" @default.
• W2055006945 modified "2023-10-16" @default.
• W2055006945 title "Bone Marrow Carcinosis and Disseminated Tumour Cells" @default.
• W2055006945 cites W1754054048 @default.
• W2055006945 cites W1870001240 @default.
• W2055006945 cites W2007897263 @default.
• W2055006945 cites W2044987814 @default.
• W2055006945 cites W2048871198 @default.
• W2055006945 cites W2062889582 @default.
• W2055006945 cites W2063140987 @default.
• W2055006945 cites W2070291618 @default.
• W2055006945 cites W2075660685 @default.
• W2055006945 cites W2076821050 @default.
• W2055006945 cites W2108296770 @default.
• W2055006945 cites W2117305280 @default.
• W2055006945 cites W2129296139 @default.
• W2055006945 cites W2136989218 @default.
• W2055006945 cites W2148096512 @default.
• W2055006945 cites W2157040071 @default.
• W2055006945 cites W2167871997 @default.
• W2055006945 cites W2314428698 @default.
• W2055006945 doi "https://doi.org/10.1159/000271606" @default.
• W2055006945 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20164654" @default.
• W2055006945 hasPublicationYear "2010" @default.
• W2055006945 type Work @default.
• W2055006945 sameAs 2055006945 @default.
• W2055006945 citedByCount "3" @default.
• W2055006945 countsByYear W20550069452013 @default.
• W2055006945 countsByYear W20550069452014 @default.
• W2055006945 crossrefType "journal-article" @default.
• W2055006945 hasAuthorship W2055006945A5027057994 @default.
• W2055006945 hasAuthorship W2055006945A5055782327 @default.
• W2055006945 hasAuthorship W2055006945A5088951258 @default.
• W2055006945 hasBestOaLocation W20550069451 @default.
• W2055006945 hasConcept C121608353 @default.
• W2055006945 hasConcept C126322002 @default.
• W2055006945 hasConcept C142724271 @default.
• W2055006945 hasConcept C2776206344 @default.
• W2055006945 hasConcept C2780007613 @default.
• W2055006945 hasConcept C2991818862 @default.
• W2055006945 hasConcept C502942594 @default.
• W2055006945 hasConcept C526805850 @default.
• W2055006945 hasConcept C71924100 @default.
• W2055006945 hasConceptScore W2055006945C121608353 @default.
• W2055006945 hasConceptScore W2055006945C126322002 @default.
• W2055006945 hasConceptScore W2055006945C142724271 @default.
• W2055006945 hasConceptScore W2055006945C2776206344 @default.
• W2055006945 hasConceptScore W2055006945C2780007613 @default.
• W2055006945 hasConceptScore W2055006945C2991818862 @default.
• W2055006945 hasConceptScore W2055006945C502942594 @default.
• W2055006945 hasConceptScore W2055006945C526805850 @default.
• W2055006945 hasConceptScore W2055006945C71924100 @default.
• W2055006945 hasIssue "1-2" @default.
• W2055006945 hasLocation W20550069451 @default.
• W2055006945 hasLocation W20550069452 @default.
• W2055006945 hasOpenAccess W2055006945 @default.
• W2055006945 hasPrimaryLocation W20550069451 @default.
• W2055006945 hasRelatedWork W1970707390 @default.
• W2055006945 hasRelatedWork W1971419911 @default.
• W2055006945 hasRelatedWork W2015676750 @default.
• W2055006945 hasRelatedWork W2027717767 @default.
• W2055006945 hasRelatedWork W2038751394 @default.
• W2055006945 hasRelatedWork W2055006945 @default.
• W2055006945 hasRelatedWork W2067699521 @default.
• W2055006945 hasRelatedWork W2371279320 @default.
• W2055006945 hasRelatedWork W3032513420 @default.
• W2055006945 hasRelatedWork W74504067 @default.
• W2055006945 hasVolume "33" @default.
• W2055006945 isParatext "false" @default.
• W2055006945 isRetracted "false" @default.
• W2055006945 magId "2055006945" @default.
• W2055006945 workType "article" @default.